Skip to search formSkip to main contentSkip to account menu

Ibandronate

Known as: (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate, 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate 
A synthetic nitrogen-containing bisphosphonate. Ibandronate inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl… 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (4)

BM 21.0955BondronatBonivaIbandronate sodium
Diphosphonatesibandronic acid 150 MG Oral Tablet

Broader (1)

ibandronic acid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Update on osteoporosis management in long-term care: focus on bisphosphonates.
Highly Cited
2004
Highly Cited
2004
Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
Highly Cited
2004
Highly Cited
2004
Intermittent Ibandronate Preserves Bone Quality and Bone Strength in the Lumbar Spine After 16 Months of Treatment in the Ovariectomized Cynomolgus Monkey
The dose‐dependent effect of ibandronate treatment on bone mass and architecture was assessed in a large animal study of OVX… 
Review
2004
Review
2004
Treatment of Idiopathic Hyperphosphatasia With Intensive Bisphosphonate Therapy
In a family with IH, a rare high turnover bone disease, two older siblings were wheelchair‐bound with severe skeletal deformity… 
Highly Cited
2004
Highly Cited
2004
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the…
Breast cancer has a significant capacity to metastasize to bone. Bisphosphonates are the standard treatment for hypocalcaemia of… 
2003
2003
Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate
The aim of the present paper was to delineate in detail the dose-dependent effects of intermittent intravenous (IV) ibandronate… 
Review
2001
Review
2001
Should bisphosphonates be the treatment of choice for metastatic bone disease?
Review
2001
Review
2001
Analysis of skeletal-related events in breast cancer and response to therapy.
Highly Cited
1996
Highly Cited
1996
Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection
Bisphosphonates (BPs) are used for the treatment of both benign and malignant diseases characterized by increased bone resorption… 
1993
1993
Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)